Michael Bishop to Biological Products
This is a "connection" page, showing publications Michael Bishop has written about Biological Products.
Connection Strength
0.459
-
Axicabtagene Ciloleucel versus Tisagenlecleucel for Relapsed or Refractory Large B Cell Lymphoma: A Systematic Review and Meta-Analysis. Transplant Cell Ther. 2024 Jun; 30(6):584.e1-584.e13.
Score: 0.181
-
The benefit of CAR T cells in older patients. Blood. 2020 06 04; 135(23):2020-2021.
Score: 0.140
-
Two-stage CD8+ CAR T-cell differentiation in patients with large B-cell lymphoma. Nat Commun. 2025 May 06; 16(1):4205.
Score: 0.049
-
Optimizing the post-CAR T monitoring period in recipients of axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel. Blood Adv. 2024 10 22; 8(20):5346-5354.
Score: 0.048
-
Patterns of Use, Outcomes, and Resource Utilization among Recipients of Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B Cell Lymphomas. Transplant Cell Ther. 2022 10; 28(10):669-676.
Score: 0.041